24H Stock Chart & Stats
€3.90
-€0.06(-1.91%)
At close: 4:00 PM EDT
€3.90
-€0.06(-1.91%)
Day’s Range― - ―
52-Week Range€2.19 - €4.09
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€326.63M
Enterprise Value€4.01B
Total Cash (Recent Filing)€552.81M
Total Debt (Recent Filing)€1.03B
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Nov 05, 2026EPS Estimate
0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.86
Shares Outstanding101,763,220
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)-31.35
Price to Sales (P/S)12.55
P/FCF Ratio-5.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.19Price Target Upside135.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.09
Revenue Forecast (FY)€41.38M
Bulls Say, Bears Say
Bulls Say
Strengthened LiquidityThe SERB upfront materially improves Hansa’s liquidity and extends its operating runway ahead of potential U.S. approval. This funding supports launch preparation, ongoing clinical development and regulatory work while reducing immediate dependence on additional external financing.
Strong Clinical And Regulatory ProgressThe positive confirmatory data provide durable support for imlifidase’s clinical utility, including improved kidney function and lower dialysis dependence. PAES results also create a pathway toward full European approval, potentially broadening long-term commercial durability.
U.S. Launch PlatformDefined regulatory timing and focused preparation across high-volume transplant centers give Hansa a concrete route to expand beyond its current European base. Successful execution could materially enlarge patient access, adoption potential and the company’s future revenue base.
Bears Say
Material Revenue DeteriorationThe sharp TTM revenue decline indicates that Hansa has not yet established consistent commercial scale, while deeply negative profitability shows that current sales do not cover the cost base. Reversing this trend is important for making the business economically self-sustaining.
Persistent Cash Burn And LeverageSustained negative operating and free cash flow means Hansa continues to consume capital to fund operations rather than generate internal financing. Combined with substantial debt and negative equity, this reduces financial flexibility if losses persist or development and launch costs remain elevated.
Higher Antibody-mediated Rejection RateThe higher observed AMR rate is a clinically important consideration that may require continued monitoring and management in practice. Even though the company reports no graft losses from AMR, the finding could influence physician confidence, treatment protocols and adoption of imlifidase.
Hansa Biopharma AB News
24H FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Hansa Biopharma AB lowest stock price was €2.19 and its highest was €4.09 in the past 12 months.
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is €326.63M.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Nov 05, 2026 which is in 25 days.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Jul 22, 2026. The company reported -€0.229 earnings per share for the quarter, missing the consensus estimate of -€0.03 by -€0.198.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is 0.55.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 101,763,220 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -€0.229 in its last earnings report, missing expectations of -€0.03. Following the earnings report the stock price went up 2.383%.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in DE:24H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
24H Stock 12 Month Forecast
Average Price Target
€9.19
▲(135.73% Upside)
Technical Analysis
Alligator Bioscience AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Cantargia AB
―